Executive leadership at CEL SCI.
GK
Geert Kersten
Detailed
Chief Executive and Financial Officer and Treasurer
CEO
DZ
Daniel Zimmerman
Detailed
Senior Vice President of Research, Cellular Immunology
ET
Eyal Talor
Detailed
Chief Scientific Officer
JC
John Cipriano
Detailed
Senior Vice President of Regulatory Affairs
PP
Patricia Prichep
Detailed
Chief Financial and Operations Officer and Corporate Secretary
Board of directors at CEL SCI.
Research analysts covering CEL SCI.
Recent press releases and 8-K filings for CVM.
CEL-SCI Reports Fiscal 2025 Results and Key Clinical Advancements
CVM
Earnings
New Projects/Investments
- CEL-SCI reported a net loss of $25.4 million for the fiscal year ended September 30, 2025, an improvement from $27.6 million in fiscal 2024, and raised $28.3 million through common stock sales. An audit opinion included an explanatory paragraph related to the company's ability to continue as a going concern.
- The company filed for Breakthrough Designation for Multikine in Saudi Arabia and completed manufacturing for its 212-patient U.S. Confirmatory Registration Study for Multikine in head and neck cancer.
- Enrollment for the U.S. Confirmatory Registration Study is anticipated to commence in Spring 2026, with plans to seek early approval in the U.S. by 2028 based on early tumor response data.
- Multikine previously demonstrated 73% long-term survival versus 45% without the drug in a Phase 3 study, and reduced the risk of death by 66% in patients with low to zero PD-L1 levels.
Dec 29, 2025, 2:00 PM
CEL-SCI Corporation Revises Shareholder Rights Agreement
CVM
Takeover Bid
- On November 18, 2025, CEL-SCI Corporation's Board of Directors approved revisions to the Company’s Shareholder Rights Agreement.
- The agreement, dated November 17, 2025, includes a dividend of one Series A Right and one Series B Right for each Common Share outstanding as of the October 30, 2025 Record Date.
- An "Acquiring Person" is defined as any entity beneficially owning 15% or more of the Company's Common Stock.
- The Rights are set to expire on October 30, 2030, unless redeemed earlier by the Board of Directors at $0.0001 per Right prior to the Distribution Date.
Nov 24, 2025, 10:00 PM
CEL-SCI Corporation Extends Shareholder Rights Agreement
CVM
Takeover Bid
- CEL-SCI Corporation's Board of Directors amended its Shareholder Rights Agreement on October 30, 2025, extending its expiration date to October 30, 2030.
- The agreement, originally adopted on November 7, 2007, includes Series A and Series B Rights.
- Each Series A Right allows the holder to purchase one Common Share at a price equal to 20% of the current per share market price.
- Series B Rights have an exercise price of $100 and will expire on October 30, 2030, if not exercised, redeemed, or exchanged.
- The Board of Directors can redeem the Rights at $.0001 per Right or exchange them for Common Shares at a one-to-one ratio under specific conditions.
Nov 5, 2025, 9:31 PM
CEL-SCI Announces Pricing of Public Offering
CVM
- CEL-SCI Corporation priced a best-efforts public offering of 1,111,200 shares of its common stock at $9.00 per share.
- The offering is expected to generate approximately $10 million in total gross proceeds before deducting fees and expenses.
- The company intends to use the net proceeds to fund the continued development of Multikine, general corporate purposes, and working capital.
- The offering is anticipated to close on August 29, 2025.
Aug 28, 2025, 2:35 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more